Taisho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taisho Pharmaceutical Co., Ltd., explained in plain language.
-
New pill aims to tame phosphorus in kidney dialysis patients
Disease control Recruiting nowThis study tests a new drug called TS-172 in 30 adults on peritoneal dialysis who have high phosphorus levels. Participants take the drug daily for several weeks to see if it can safely bring their phosphorus down to a target range. The goal is to find a better way to manage this…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill aims to tame dangerous phosphate levels in dialysis patients
Disease control Recruiting nowThis study tests a new drug called TS-172 in 30 adults on hemodialysis who have high phosphate levels. Participants take the drug daily for a period, and researchers check if their phosphate levels drop to a target range. The goal is to see if TS-172 can help control phosphate, a…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for dialysis patients: drug targets dangerous phosphorus levels
Disease control Recruiting nowThis study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels. Participants will take TS-172 or a placebo alongside their usual phosphate binders. The goal is to see if TS-172 helps more patients reach safe phosphorus levels, wh…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to tame dangerous phosphate in kidney patients
Disease control Recruiting nowThis phase 3 study tests a new drug called TS-172 in 300 adults on hemodialysis who have high phosphate levels. Participants take the pill daily for up to a year to see if it safely and effectively controls phosphate. The goal is to offer a better treatment option for a common co…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug TS-172 tested in patients with liver impairment
Knowledge-focused Recruiting nowThis early-stage study is testing how the drug TS-172 behaves in the bodies of people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to see if liver function affects how the drug is processed. The study involves 24 Japanese adults and is…
Phase: PHASE1 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC